Stockscreener 앱 받기
9.3679
4.12%
-0.4021
전일 마감가:
$9.77
열려 있는:
$9.5
하루 거래량:
16,586
Relative Volume:
0.20
시가총액:
$352.94M
수익:
$4.71M
순이익/손실:
$-46.77M
주가수익비율:
-5.5788
EPS:
-1.6792
순현금흐름:
$-60.34M
1주 성능:
+2.38%
1개월 성능:
+17.56%
6개월 성능:
+7.06%
1년 성능:
+102.77%
1일 변동 폭
$9.30
$9.50
1주일 범위
$9.21
$10.07
52주 변동 폭
$4.00
$20.00
Nyxoah Sa Stock (NYXH) Company Profile
NYXH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
9.3679 | 352.94M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
545.25 | 193.26B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
235.74 | 68.18B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
83.71 | 41.56B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
234.99 | 34.52B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
334.69 | 24.14B | 2.88B | 499.60M | 321.60M | 6.74 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-31 | 개시 | H.C. Wainwright | Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2022-04-21 | 개시 | Oppenheimer | Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Peer Perform |
| 2021-12-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Nyxoah Sa 주식(NYXH)의 최신 뉴스
Retail investors are Nyxoah S.A.'s (EBR:NYXH) biggest owners and were rewarded after market cap rose by €38m last week - Simply Wall St
Nyxoah (NASDAQ:NYXH) Stock Price Up 1.2% – Here’s What Happened - Defense World
Nyxoah Receives Transparency Notification from BlackRock, Inc. - TipRanks
Nyxoah: The Future Of OSA (NASDAQ:NYXH) - Seeking Alpha
How the (NYXH) price action is used to our Advantage - Stock Traders Daily
Publication relating to transparency notifications - GlobeNewswire
BlackRock Takes 3% Stake in Medical Device Maker Nyxoah in Strategic Investment Move - StockTitan
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 - Finansavisen
(NYXH) Investment Analysis and Advice - Stock Traders Daily
Nyxoah's SWOT analysis: sleep apnea innovator faces growth hurdles - Investing.com
Nyxoah's SWOT analysis: sleep apnea innovator faces growth hurdles By Investing.com - Investing.com UK
Nyxoah's nerve stimulation device meets endpoints in sleep apnoea studyMedical Device Network - Oficjalny Portal Gminy Brzesko
HC Wainwright Reaffirms “Buy” Rating for Nyxoah (NASDAQ:NYXH) - Defense World
Nyxoah’s Genio Neurostimulator for OSA Launches in England - Sleep Review
Nyxoah's SWOT analysis: sleep apnea innovator's stock poised for US launch - Investing.com
Nyxoah Launches Revolutionary Sleep Apnea Treatment in England with First NHS-Covered Implants - StockTitan
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England - GlobeNewswire
Nyxoah Announces Commercial Launch of Genio Innovative Therapy in England - Marketscreener.com
Where are the Opportunities in (NYXH) - Stock Traders Daily
Nyxoah Updates Share Capital and Voting Rights - TipRanks
Information on the Total Number of Voting Rights And Shares: Nyxoah - The Korea Bizwire
Information on the total number of voting rights and shares - GlobeNewswire
Objective long/short (NYXH) Report - Stock Traders Daily
Nyxoah (NASDAQ:NYXH) vs. Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast - Defense World
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Korea Bizwire
Nyxoah to Present at Healthcare Conference Amidst Growth - TipRanks
Nyxoah to Present Sleep Apnea Innovation at Piper Sandler Healthcare Conference | NYXH Stock News - StockTitan
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024: Nyxoah - The Korea Bizwire
Nyxoah Schedules Special Meeting to Vote on EIB Loan Agreement Terms | NYXH Stock News - StockTitan
Publication Relating to Transparency Notifications: Nyxoah - The Korea Bizwire
Nyxoah’s Voting Rights Shift with ResMed Stake - TipRanks
ResMed's Stake in Nyxoah Drops Below 5% Threshold in Latest Holdings Update | NYXH Stock News - StockTitan
Publication relating to transparency notifications, Business Wires News - AsiaOne
Nyxoah S.A. (NASDAQ:NYXH) Short Interest Down 17.4% in October - MarketBeat
Nyxoah's SWOT analysis: sleep apnea device maker's stock poised for growth - Investing.com India
Nyxoah Third Quarter 2024 Earnings: €0.50 loss per share (vs €0.27 loss in 3Q 2023) - Simply Wall St
Nyxoah Reports Third Quarter Financial and Operating Results - Wahanariau
Nyxoah sales jump 30% to €1.3 million in Q3 2024 - Medical Buyer
Nyxoah SA Reports Growth Amid Clinical Advances - TipRanks
EQS-News: Nyxoah Reports Third Quarter Financial and Operating Results - sharewise
Nyxoah Eyes Strong US Launch Amid Financial Growth - TipRanks
Nyxoah S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nyxoah Reports Third Quarter Financial and Operating Results, Business Wires News - AsiaOne
(NYXH) Investment Report - Stock Traders Daily
Nyxoah Q3 Revenue Surges 30% as FDA Approval Timeline Stays on Track for 2025 - StockTitan
Nyxoah SA (NYXH) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Nyxoah SA Announces CFO Changes - Marketscreener.com
Nyxoah participates in a conference call with Cantor Fitzgerald - TipRanks
Nyxoah Appoints John Landry as Chief Financial Officer - The Manila Times
Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Nyxoah Sa (NYXH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
자본화:
|
볼륨(24시간):